Kamyar Kalantar-Zadeh M.D. to Ferric Compounds
This is a "connection" page, showing publications Kamyar Kalantar-Zadeh M.D. has written about Ferric Compounds.
Connection Strength
3.468
-
Management of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis. BMC Nephrol. 2024 Jun 17; 25(1):197.
Score: 0.890
-
Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study. BMC Nephrol. 2019 10 29; 20(1):396.
Score: 0.646
-
One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis. J Ren Nutr. 2019 09; 29(5):428-437.
Score: 0.612
-
Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide. Am J Nephrol. 2018; 47(3):153-161.
Score: 0.576
-
Iron therapy in chronic kidney disease: current controversies. J Ren Care. 2009 Dec; 35 Suppl 2:14-24.
Score: 0.325
-
Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence. J Nephrol. 2022 04; 35(3):875-888.
Score: 0.189
-
Parenteral iron therapy and phosphorus homeostasis: A review. Am J Hematol. 2021 05 01; 96(5):606-616.
Score: 0.176
-
Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis. 2003 Oct; 42(4):761-73.
Score: 0.053